The Second International Symposium on Acute Promyelocytic Leukemia (APL) was held in Rome in 12-14 November 1997. Clinical and basic investigators had the opportunity to discuss in this meeting the important advances in the biology and treatment of this disease achieved in the last 4 years, since the First Roman Symposium was held in 1993. The first part of the meeting was dedicated to relevant aspects of laboratory research, and included the following topics: molecular mechanisms of leukemogenesis and of response/resistance to retinoids, biologic and therapeutic effects of new agents such as arsenicals and novel synthetic retinoids; characterization of APL heterogeneity at the morphological, cytogenetic and immunophenotypic level. The updated results of large cooperative clinical trials using variable combinations of all-trans retinoic acid (ATRA) and chemotherapy were presented by the respective group chairmen, and formed the 'core' part of the meeting. These studies, which in most cases integrated the molecular assessment of response to treatment, provided a stimulating framework for an intense debate on the most appropriate frontline treatment options to be adopted in the future. The last day was dedicated to special entities such as APL in the elderly and in the child, as well as the role of bone marrow transplantation. The prognostic value of molecular monitoring studies was also discussed in the final session of the meeting. In this article, we review the major advances and controversial issues in APL biology and treatment discussed in this symposium and emerging from very recent publications. We would like to credit the successful outcome of this meeting to the active and generous input of all invited speakers and to participants from all over the world who provided constructive and fruitful discussions.
chromosome 11 8 ( Table 1) . PML, PLZF, NPM and NuMA are not structurally related, but are nuclear proteins that contain an N-terminal protein-protein interaction domain. RAR␣ is one of the nuclear retinoid receptors that mediate action of ATRA on myeloid differentiation. [9] [10] [11] [12] When fused to RAR␣, the resulting chimeric proteins possess an identical RAR␣ moiety (B-F regions of the receptor), comprising the DNA, corepressor, coactivator and ATRA binding regions. The occurrence of a unique RAR fragment fused to multiple partners suggests that RA-target genes are downstream effectors of their activities. [1] [2] [3] [4] [5] APLs with the PML/RAR␣, PLZF/RAR␣, NPM/RAR␣ or NuMA/RAR␣ are clinically and phenotypically very similar but differ in their sensitivity to ATRA. In particular, APL patients and cells expressing PLZF/RAR␣ fail to differentiate in response to ATRA. 13 Expression of both PML/RAR␣ or PLZF/RAR␣ into hematopoietic precursor lines induces a differentiation block and promotes survival and both PML/RAR␣ and PLZF/RAR␣ transgenic mice develop an APL-like disease. [14] [15] [16] [17] [18] [19] [20] This leukemia is ATRA-sensitive in PML/RAR␣ transgenic mice and relatively ATRA-resistant in PLZF/RAR␣ mice. Accordingly, PML/RAR␣, but not PLZF/RAR␣, increases ATRA sensitivity of hematopoietic precursor cells.
Thus, both fusion proteins appear actively involved in conferring a differentiation block to leukemic cells, while only PML/RAR␣ confers ATRA sensitivity. 14, 15 ATRA probably converts PML/RAR␣, but not PLZF/RAR␣, to an active inducer of myeloid differentiation possibly by triggering its transcriptional activator function on specific ATRA target genes. Notably, structural and functional alterations of PML/RAR␣ may cause ATRA resistance in APL-derived NB4 cell lines.
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Retinoic acid receptors
Retinoids, natural or synthetic derivatives of vitamin A, are necessary dietary constituents that exert dramatic effects on development, cell proliferation and differentiation by regulating the expression of specific genes. 9, 10, 24 Biological effects of retinoids appear to be mediated by two classes of nuclear receptor proteins of the steroid and thyroid hormone superfamily, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). RARs (␣, ␤ and ␥) are activated by both ATRA and 9-cis-RA, whereas RXRs (␣, ␤ and ␥) are activated by 9-cis-RA only. 9, 10 As the other members of this superfamily, retinoid receptors are ligand-inducible transcriptional regulatory factors and RARs must heterodimerize with RXRs for effective DNA binding and transactivation. 9, 10 It has recently been shown that RARs associate with co-regulatory proteins, such as N-CoR and SMRT, in the absence of ligand. These repressors, in turn, associate with Sin3 and histone 81 deacetylase proteins to form a transcriptional repressor complex. 24, 25 Ligand binding is proposed to dissociate the repressor complex and to recruit a multisubunit activation complex that possesses histone acetyltransferase activity. 25 The PML gene product PML is a member of the RING finger family that is ubiquitously expressed in tissues within large multiprotein nuclear structures termed nuclear bodies (NBs) and acts as a growth suppressor in vitro. [26] [27] [28] [29] PML interacts and co-localizes with PIC-1, an ubiquitin-like molecule also called SUMO-1 (for small ubiquitin-related modifier) that was isolated as a yeast two hybrid partner of PML. 30 The characterization of ubiquitin-like (UBL) genes and their biological roles was the subject of Solomon's presentation. E Solomon (London, UK) proposed that PIC-1 or SUMO-1 should be called in the future UBL-1, for ubiquitin like-1 protein. UBL-1 is highly homologous to a S. cerevisiae gene called SMT3, which is believed to be important for normal DNA replication, nuclear division and mitotic spindle integrity. 31 The isolation of mouse UBL-1 cDNA revealed an homology of nearly 100% of the predicted amino acid sequence between mouse and human. This extreme conservation stresses the importance of this gene family. The mouse UBL-1 gene was found to map to chromosome 1, which should correspond to chromosome 2 in humans. A number of mouse and human pseudogenes were pulled out during the isolation of the genomic sequence. 32 Immunofluorescence studies show that UBL-1 co-localizes with PML into the PML-NBs and that the immunostaining patterns of both UBL-1 and PML are disrupted and appear diffuse in APL cells. After ATRA treatment, the PML and UBL-1 proteins entirely co-localized. 30 In addition, human and murine UBL-1 were found covalently linked to other proteins such as human DNA repair proteins (RAD51 and RAD52), the cell death domain of FAS and a Ran GTPase-activating protein (Ran-GAP1) that is required for functional nuclear transport. 31, 32 These data suggest that conjugation with UBL-1 might regulate PML degradation or transport into the nucleus or its interaction with the nuclear matrix.
Nuclear localization of PML
A Dejean (Paris, France) presented work aimed to link the therapeutic effect of ATRA in promoting myeloid cell differentiation to its effect in reorganizing the nucleus. Immunofluorescence studies have shown that the native PML protein concentrates in the nucleus within discrete nuclear structures identified as a subtype of nuclear bodies. [26] [27] [28] The PML bodies correspond to a new type of multiprotein complex in which two components (PML and SP100) have been genetically characterized to date. The expression of PML and SP100, as well as the number of NBs, are strongly up-regulated by treatment with interferon ␣. 33 These structures can be disrupted by environmental stimuli, such as heat shock and viral proteins (herpes simplex, adenovirus, CMV). Thus, these structures could correspond to active sites for some nuclear functions or to storage compartments for cellular regulatory proteins. Since the expression of PML/RAR␣ in APL cells alters the PML-NBs and their restoration correlates with disease remission, their function is a key question. PML/RAR␣ could exert a dominant negative effect by sequestering and diverting a number of proteins from their natural site of action (including RXR and other nuclear co-factors). Thus, the therapeutic effect of ATRA in promoting myeloid cell differentiation could be related to the drastic reorganization of the nucleus which occurs in APL cells after ATRA treatment.
Molecular mechanisms of APL leukemogenesis and response to ATRA
ATRA treatment induces a degradation of PML/RAR␣ fusion protein 34, 35 an event that has been proposed to account for the induction of APL cells differentiation by ATRA. Downregulation of PML/RAR␣ by ATRA occurs at the post-translational level, 35 and is prevented by proteasome inhibitors. 34 A possible role for the proteasome pathway in the ATRA induced degradation of PML/RARa is indicated by the fact that PML is associated with ubiquitin-related proteins. [30] [31] [32] 36 However, the proteasome has been found to be involved in cellular pathways leading to apoptosis due to caspase activation. 37, 38 Caspases are a family of cysteine proteases with aspartic acid substrate specificity, thought to be key effectors of cellular apoptosis in multicellular organisms. 39 C Nervi (Rome, Italy) showed that caspases and, in particular, a caspase3-like activity, mediate the ATRA-induced degradation of PML/RAR␣. 40 Using different caspase inhibitor peptides, the ATRA-induced PML/RAR␣ degradation could be prevented and the contribution of PML/RAR␣ degradation and PML-NBs reorganization to ATRA response of APL cells directly tested. The results show that in PML/RAR␣-expressing cells, including blasts from APL patients, the extent of PML/RAR␣ cleavage directly correlates with the ability of ATRA to restore the normal PML nuclear bodies (NBs) pattern. However, ATRA-induced APL cell differentiation is not prevented (but is actually increased), by the persistence of the fusion product and can occur also in the absence of normally structured PML-NBs. 40 H de Thé (Paris, France) presented data that the Review F Lo Coco et al 1868 microspeckled pattern, seen in PLZF/RAR␣-expressing primary blasts and transfected cells (using either ␣-PLZF or ␣-RAR antibodies) disappears after overnight exposure to ATRA. Thus, ATRA fails to induce terminal differentiation of PLZF/RAR␣-APL blasts despite apparent degradation of the PLZF/RAR␣ fusion protein. 15 Together these findings show that the degradation of the chimeric proteins is not a crucial event for the differentiative response of APL cells to ATRA and that ATRA-induced differentiation does not require the integrity of the PML-NBs.
PG Pelicci (Milan, Italy), A Dejean (Paris, France) and WH Miller (Montreal, Canada) presented data that both PML/RAR␣ and PLZF/RAR␣ are associated with a transcription corepressor complex that is involved in both the development of APL and in the ability of patients to respond to retinoids. 20, [41] [42] [43] [44] [45] Their studies indicate that, in the absence of ligand, both PML/RAR␣ and PLZF/RAR␣ (similarly to wild-type RAR␣) are tightly bound to the transcriptional co-repressors N-CoR and SMRT through the hinge region of the RAR␣ moiety. SMRT and N-CoR associate with the co-repressor Sin3 and histone deacetylase proteins to form a transcriptional repressor complex. 46, 47 Thus, binding of PML/RAR␣ and PLZF/RAR␣ to transcriptional co-repressors leads to the formation of a repressive chromatin structure. The affinity of the interaction between these two oncoproteins and transcriptional corepressors is much higher than that of wild-type RAR␣ but appears critical for their leukemogenetic activity. In fact, PG Pelicci showed that the mutation of the region of PML/RAR␣ which binds N-CoR causes the loss of the ability of PML/RAR␣ to block differentiation, without affecting its capacity to increase ATRA-induced differentiation in vitro. 43 Indeed, much higher ATRA concentrations are required for transcriptional corepressors to dissociate from PML/RAR␣ than from wild-type RAR. In contrast, two distinct N-CoR/SMRT interaction regions are present in the PLZF/RAR␣ fusion. One in the COR box of the RAR␣ moiety (that is shared with RAR␣ and PML/RAR␣) and another in the PLZF moiety. ATRA addition fully releases the complex interacting with the RAR␣ component of PLZF/RAR␣, but not that interacting with the PLZF moiety, which appears totally resistant to ATRA. Notably, inhibition of the repression block mediated by the histone deacetylase enzymatic activity by treatment with Trichostatin A (TSA) or sodium butyrate is able to synergize with ATRA to convert PLZF/RAR␣ from a repressor of transcription to an activator of ATRA target genes and myeloid differentiation. WH Miller presented data showing that TSA also induces a partial restoration of the ATRA-induced differentiation in RAresistant NB4-R4 cell lines, in which a point mutation in the PML/RAR␣ E domain causes a loss of ligand binding (see below). 23, 44 Together, these studies 20, [41] [42] [43] [44] [45] demonstrate that the inability of APL-fusion proteins to dissociate from the nuclear corepressor complex at physiological ATRA concentrations is critical for PML/RAR␣ and PLZF/RAR␣ leukemogenic activity. The different stability of the fusion/corepressor complex in the presence of pharmacologic levels of ATRA is responsible for their differences in ATRA sensitivity.
Retinoid-resistance
To study the molecular basis of the acquired resistance to ATRA that occurs in APL patients following treatments with ATRA alone, WH Miller developed stable-retinoid resistant subclones of the APL cell line NB4. 22, 23 These cell lines retain the t(15;17) and appear to be resistant also to a variety of retinoids including those that do not seem to bind CRABP. Immunohistochemical studies indicate that in retinoid-resistant NB4 subclones, ATRA treatment fails to alter the microparticulate nuclear pattern of PML. [21] [22] [23] These subclones present altered retinoid binding properties probably due to an abnormal PML/RAR␣ expression, structure and function. [21] [22] [23] In fact, the DNA binding activity and the stimulation of transcription of an RARE driven CAT-reporter gene induced by ATRA is significantly decreased in these cells compared to the NB4 parental cell line. 22, 23 In addition, a partial loss of retinoidinduced gene expression in these cells is present. In one of these subclones (R4) a lysine:proline point mutation in the ligand binding domain of the RAR␣ portion of the fusion protein was found. This proline substitution causes loss of ligand binding of PML/RAR␣, but no loss of binding to RAREs or nuclear co-repressors. 23, 44 A similar mutation was detected in APL blasts from three ATRA-resistant patients by Gallagher et al. 48 More recently, Imaizumi and co-workers described the acquisition of point mutations in the ligand binding region of RAR␣/E-domain in two patients who exhibited ATRA-resistance at relapse. 49 Such mutations, which resulted in amino acid changes (Arg:Gln and Met:Leu, respectively) in the affected domain, were associated with decreased ligand-dependent transcriptional activity of the mutant PML/RAR␣ protein as compared to that of wild-type PML/RAR␣. Thus, the resistant phenotype and mechanism found in cell lines in vitro may be paralleled by a very similar mechanism in APL patients.
Molecular basis of clinical response to arsenic trioxide
Arsenic trioxide has been identified as a potent antileukemic agent in both ATRA-sensitive and ATRA-resistant APL patients. 50, 51 It acts by triggering apoptosis without differentiation of APL blasts. [50] [51] [52] [53] [54] [55] Similarly to ATRA, in APL cells arsenic trioxide rapidly induces a drastic reorganization of the nucleus characterized by the restoration of intact PML NBs that appear increased in size, followed by a progressive degradation of the PML/RAR␣ protein. 50, 54, 55 Thus, both ATRA and arsenic may induce re-assembly of PML-NBs as a consequence of the induction of PML/RAR␣ degradation. 52 ,55 WH Miller showed that arsenic trioxide induces apoptosis, reassembly of PML-NBs and loss of PML/RAR␣ also in a large panel of ATRA-resistant NB4 cell lines. 55 Indeed, studies on fresh APL cells in vitro show that the addition of arsenic interferes with the capacity of ATRA to induce cellular differentiation, while the addition of ATRA reduces cell apoptosis induced by arsenic. 55 In contrast, data presented by H de Thé indicate a cooperative effect on differentiation and apoptosis by the combined treatment with arsenic and ATRA in arsenic resistant NB4 subclones. 52 Notably, fresh blasts from a t(11;17) APL patient were found to be totally unresponsive to arsenic treatment in vitro. Further studies of the mechanism of action of these two agents may better define their respective roles in the treatment of APL and, possibly, of other tumors. The restoration of PML-NBs by arsenic is not confined to APL. In non-APL cells, arsenic does not induce significant degradation of PML, but rather triggers its post-translational attachment to SUMO-1 (also called PIC-1, and proposed by E Salomon to be renamed UBL-1). 36 This subsequently re-targets PML from the nuclear matrix to the nuclear bodies. In fact, experimental evidence presented by A Dejean and H de Thé indicate that arsenic induces a very fast movement of the 90 kDa unmodified PML from the nuclear soluble fraction to the nuclear matrix, where SUMO-1 oligo-and poly-modified forms of PML are associated with components of the PML NBs. The formation of these modified SUMO-1-PML conjugated forms (which is a phosphorylation-dependent process), increases considerably after arsenic treatment. 36 Together these data suggest that post-translational modifications by SUMO1 are involved in the trafficking of proteins between different subcellular structures and provide additional evidence that ubiquitin-like modifications are not restricted to degradation signals.
Modern approach for integrated diagnosis of APL: advantages and pitfalls of the various techniques
Given its unique response to a specific therapy, correct identification of APL is of the utmost importance in the clinical practice. [1] [2] [3] [4] [5] 56, 57 Moreover, early institution of ATRA therapy seems effective in the control of the APL-associated coagulopathy, which accounts for the frequently recorded early hemorrhagic deaths and whose prompt correction is therefore essential for successful outcome. [58] [59] [60] [61] [62] [63] A diagnostic approach should therefore be outlined which defines the impact of each test in either therapeutic choice or prognostic assessment.
Most recent characterization data summarized in the following paragraphs indicate that each technique carries its own pitfalls and advantages. To properly tackle the issue of diagnostic assessment, it is appropriate to distinguish two groups of procedures: (1) those mandatory for patient entering into tailored (ie ATRA-containing) treatment; and (2) those useful for better dissecting potentially distinct categories and/or for monitoring minimal residual disease. For therapeutic decision, the crucial point is cytogenetic or molecular demonstration of the unique t(15;17) abnormality, which is by no doubt the condicio sine qua non for eligibility into ATRAcontaining protocols. As first demonstrated in 1992 by Miller et al, 64 RT-PCR allows better definition of this aberration and clearly defines patients responsive to ATRA. In fact, among cases with apparently normal metaphases or non-evaluable karyotypes, only those with RT-PCR detectable PML/RAR␣ responded to ATRA. 64 This observation was further confirmed in several larger studies. 65 It is now universally accepted that PML/RAR␣ is the real hallmark of this disease, as it may be found in the absence of t(15;17). [1] [2] [3] [4] [5] [65] [66] [67] [68] [69] [70] [71] Therefore, it is important to emphasize that negative t(15;17) does not preclude a diagnosis of APL. For example, in the MRC ATRA study, only 87% of patients with molecular evidence of APL had the t(15;17) (failures and cryptic translocations accounting for the remaining 13%). 72 Demonstration of the t(15;17) by conventional karyotype or FISH, however, is specific for APL and PML/RAR␣ expression. Identification of microspeckled PML distribution by anti-PML monoclonal antibodies used in immunocytochemistry or immunofluorescence provides an equally specific approach to allow patient entry into tailored protocols if RT-PCR evaluation is not available. 73, 74 Compared to RT-PCR, the analysis of PML localization offers the additional advantage of rapidity (2-3 h), low cost, and simplicity of execution/interpretation. 73, 74 Thus, its use might be recommended in small centers not equipped or trained for molecular studies. However, it is worth emphasizing that RT-PCR is the only approach allowing precise definition of the PML/RAR␣ isoform (long or bcrl-2 vs short or bcr3). This, in turn, provides a target for minimal residual disease evaluation, and the definition of the appropriate RT-PCR strategy (including the correct primer set) to be used for the individual patient during follow-up. 65 The MRC, GIMEMA and PETHEMA groups found that approximately 10% of cases morphologically defined as M3 in multicenter trials lacked the specific fusion gene after RT-PCR. 72, 75, 76 It is important that, in cases with typical M3 morphology, treatment is not delayed until genetic characterization is available. In fact, unless performed on-site, the execution of cytogenetic and RT-PCR analyses may require several days, particularly in large cooperative studies in which diagnostic material is centrally reviewed. On the other hand, cases with clear evidence of PML/RAR␣ by RT-PCR should always be further characterized with complete karyotyping on banded metaphases for diagnostic confirmation and for the identification of potentially relevant additional abnormalities. Finally, immunophenotype has an important role, as we will discuss below, due to its capability of identifying in AML a surface marker profile consistently associated with (although not unique for) APL. In cases with uncertain morphology (M3v and others) certain immunophenotypic patterns are extremely useful for fostering further characterization, in particular genetic demonstration of the specific abnormality. Whether distinct APL immunophenotypic subsets bear prognostic significance is the subject of presently ongoing investigation. Advantages and pitfalls of diagnostic characterization techniques used in APL are shown in Table 2 .
Diagnostic and differentiation-induced cytological features
Because recognition of the specific genetic lesion appears mandatory for patient eligibility into ATRA-containing protocols, in the past few years the role of molecular biology for diagnostic assessment has become increasingly relevant. Notwithstanding, morphologic characterization of this entity remains fundamental. Firstly, more than 90% of true APLs (ie genetically confirmed) are easily and rapidly diagnosed upon light microscopy based on the characteristic cytological features. Secondly, morphologic analysis is relevant to the identification of less typical variants (microgranular type M3v, basophil-like M3) which may mimic other FAB subsets.
However, cases of suspect M3v [77] [78] [79] [80] showing scarcely granulated blasts, strong myeloperoxidase positivity, bilobed or folded nuclei and monocytoid aspect should be immediately referred to molecular biology and/or cytogenetic laboratories for search of the specific genetic abnormality. In the clinical practice, one of the key diagnostic issues is when to alert molecular biologists for RT-PCR of the PML/RAR␣ hybrid in AML. In other words, the question is: given a possible false negative result of karyotyping (eg poor mitoses or occurrence of a cryptic translocation) and the time required, should we search for the presence of PML/RAR␣ in all AML cases regardless of FAB definition? In our experience (University La Sapienza, Rome), none of 100 non-M3 AML analyzed retrospectively by Southern blot showed rearrangement of the RAR␣ gene. On the contrary, as we have mentioned before, approximately 10% of patients initially classified as FAB M3 and registered in the GIMEMA trial on the basis of morphology alone were subsequently excluded due to lack of PML/RAR␣ in leukemic cells. 75 In this context, it is important to consider that translocations other than t(15;17) involving the RAR␣ locus (ie t11;17, t5;17) may result in an APL-like phenotype. [6] [7] [8] Although extremely rare, t(11;17)-APL needs to be distinguished from PML/RAR␣-positive cases due to distinct therapeutic requirements. 13 As to the t(5;17), which involves the nucleophosmin (NPM) gene on 5q35 and RAR␣ on 17q21, 7 a recent report indicated that this subset is responsive to ATRA in vitro. 81 More detailed information on either forms, as well as on the recently described t(11;17) involving the NuMA on 11q13, 8 would be needed for a better biologic and clinical characterization of these rare entities.
Another area of morphological research deserving special attention is the study of differentiation pathways during retinoic acid therapy. Baseline and ATRA-induced morphologic aspects of APL were discussed in the symposium by G Flandrin (Paris, France) and V Liso (Bari, Italy). Morphological signs of response usually start appearing after the first week of ATRA, and consist of a decrease of cytoplasmic granules and basophilia, condensation of nuclear chromatin, appearance of cytoplasmic vacuolization. These features are accompanied by progressive band-like aspect of the nuclei in the following days. 62 Recognition of these morphological changes is a fundamental criterion for patient initial response to ATRA, though they may show some variability, also depending on the concomitance and type of combined chemotherapy. Interestingly, patients receiving identical ATRA-containing treatments may show heterogeneous morphological changes. For example, in patients treated with simultaneous idarubicin and ATRA, the post-induction phase is accompanied in most patients by marrow aplasia, but a non-hypoplastic pattern is also observed in some others. The reasons for this heterogeneous morphologic behavior appear unclear and deserve tailored studies correlating these aspects with molecular features and prognosis. Also, it remains to be established whether a morphologic pattern of rapid differentiation (ie within 20-30 days) is associated with better outcome with respect to slow maturation pattern.
Karyotypic variants and cryptic translocations
R Berger (Paris, France) reviewed karyotypic aspects of APL and proposed some technical recommendations for improving the rate of successful karyotyping. These include marrow in vitro culture (up to 48 h), which is less likely than direct preparations to result in the analysis of normal elements (eg erythroblasts) not belonging to the leukemic clone. 82 In recent years, cytogenetic studies have contributed the identification of numerous variant translocations including relatively frequent rearrangements of 15, 17 and a third chromosome (ie chomosomes 1, 8, 14 and others, [83] [84] [85] [86] [87] and more rare translocations involving RAR␣ on chromosome 17 and PLZF chromosome band 11q23 or NPM from chromosome 5q35. 6, 7 Most recently, the fusion between the NuMA gene on chromosome band 11q13 and RAR␣ has been described as a single case report. 8 Important additional information, which may only be provided by standard karyotyping, is the existence of secondary changes (trisomy 8, and others) apart from t(15;17). These are found in approximately 15% to 30% of cases. [1] [2] [3] [4] [5] Although their prognostic significance is still uncertain, it seems that such additional lesions are not associated with unfavorable outcome as they are, for example, in other AML subsets and in CML. 88 Fluorescence in situ hybridization (FISH) with specific RAR␣ and PML probes used either in metaphase or interphase preparations may add important information as to the existence of masked translocations in cases with apparently normal karyotype. 69, 71 A Biondi (Monza, Italy) reported the preliminary results of a European workshop on M3-like leukemias without the classical t(15;17), which were reviewed morphologically and analyzed by a combination of RT-PCR, Southern blot and FISH. At the cytogenetic analysis, this series included cases with normal karyotype, cases with the t(11;17) and cases involving chromosome 15, 17 and a third chromosome. Results of molecular analyses with RT-PCR and FISH showed the frequent occurrence of cryptic PML/RAR␣ translocations formed as a result of insertion, whereas all the t(11;17) cases had the PLZF/RAR␣ fusion gene as expected. The occurrence of cryptic PML/RAR␣ fusion as the most frequent finding in morphologically typical APL lacking the t(15;17) was reported in the symposium and in a recent study by D Grimwade (London, UK). 71 Importantly, these cases showed the characteristic microparticulate pattern of PML distribution when analyzed with a specific antibody, indicative of disruption of the nuclear bodies, whereas all t(11;17) cases displayed the typical non-APL pattern of PML localization into discrete nuclear bodies. 71 These studies clearly contradict earlier cytogenetic reports claiming that a t(15;17) could be found in every APL patient, 89 and emphasize the need of combining molecular and karyotypic characterization for diagnostic purposes. The final analysis of large number of cases enrolled into cooperative trials (US Intergroup, European APL '93, GIMEMA-AIDA, MRC-ATRA, PETHEMA LAP'96, JALSG-AML92 and others), which in most cases involve multiparametric diagnostic characterization, should provide relevant information about the incidence and clinical significance of variant and cryptic translocations in APL.
Immunophenotypic features
E Paietta (Bronx, New York) discussed the utility of immunophenotyping in APL. Known distinctive features of this entity include the lack or low expression of HLA-DR and of CD34, combined to positivity for CD13, CD33 and CD9. [90] [91] [92] [93] [94] More recently, absence of the multidrug resistance mediator P-glycoprotein (P-gp) and expression of CD117 and CD15s have been reported. 95 Interestingly, such surface marker pattern remains consistent in the two main subtypes M3 and M3 microgranular variant (M3v), in spite of their morphological heterogeneity. Although highly distinctive, this antigenic profile is neither unique nor diagnostic, and cases showing this phenotype but lacking the specific genetic lesion have been reported. 91 Nonetheless, surface marker analysis is relevant for diagnostic identification of cases with uncertain morphology (ie M3v or others) which deserve molecular search of PML/RAR␣. Other antigens infrequently expressed on APL blasts are CD2, CD34 and CD19. 94 Among these, CD2 positivity has been variably associated with the M3v subset or with the short (bcr3) PML/RAR␣ transcript type. 96, 97 By studying molecular and immunophenotypic features of both children and adults with APL, we recently found that CD2 is associated with FAB M3v in the pediatric population and with bcr3 in adults. 94 Thus, it is conceivable that the higher incidence of CD2 expression described in children reflects the higher frequency of M3v.
A recently described immunophenotypic subset, the NK (for natural killer)-cell myeloid leukemia characterized by CD56 expression, may be misdiagnosed as APL upon morphologic analysis. 98 As remarked by E Paietta, this and other immunophenotypic subsets showing only subtle differences compared to classical APL deserve special attention and require molecular investigation for the presence of the specific genetic lesion. Despite these limitations, which clearly indicate that lack of absolute specificity of the surface marker profile, immunophenotypic characterization is of considerable help for diagnostic studies, particularly in light of its rapidity, widespread availability and low cost.
A further advantage of surface marker analysis is the potential to differentiate discrete clinical entities such as, for example, CD34-positive or CD2-positive APL. Most recently, a small subset of patients who co-expressed the B cell marker CD19 has been reported in association with high white blood cell count, ie an established negative prognostic factor in patients with APL.
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The APL-associated coagulopathy in the ATRA era Early hemorrhagic deaths due to the associated coagulopathy were recorded in up to 30-40% of APL patients prior to the use of ATRA. [1] [2] [3] [4] [5] 99 Presenting clinical features and laboratory parameters indicating a hemorrhagic diathesis with rapid consumption of platelets and coagulation factors were typically worsened with the start of chemotherapy, resulting in life-threatening complications including intracranial bleeding. [1] [2] [3] [4] [5] 99 Because the disease has otherwise a favorable prognosis, overcoming the hemorrhagic risk has long since been considered crucial for successful outcome.
The introduction of ATRA in the front-line therapy has improved the control of APL-associated coagulopathy. This impact was discussed in the symposium by T Barbui (Bergamo, Italy) and extensively reviewed in the literature.
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The pathogenesis of this coagulopathy is rather complex and can involve several mechanisms including activation of the coagulation, fibrinolysis, and non-specific proteolysis systems, as demonstrated by modern laboratory assessment. Activation of the coagulation is revealed by elevated thrombinantithrombin (TAT) complexes, prothrombin fragment 1 + 2 and fibrinopeptide A (FPA) plasma levels, whereas high fibrinogen-fibrin degradation products (FDP), D-dimer and urokinase-type plasminogen activator (u-PA) levels with concomitantly decreased plasminogen and ␣-2-antiplasmin indicate hyperfibrinolysis. Finally, elevated leukocyte elastase and fibrinogen split products of elastase testify to the activity of non-specific proteases. Thrombocytopenia due to either bone marrow invasion or platelet consumption following intravascular coagulation is found in the vast majority of patients at presentation. 59, 63 The improvement of clinical and laboratory signs accompanying this coagulopathy was soon observed in earlier studies employing ATRA alone for remission induction. 58, 59 Usually, decrease of fibrinolysis products and clotting activation markers is detected within the first week of therapy. Such improvement of laboratory parameters is accompanied by prompt resolution of associated clinical symptoms. Notably, such benefits are also observed in patients receiving simultaneous chemotherapy in addition to ATRA. [60] [61] [62] [63] The differentiation process which follows ATRA administration reduces significantly the expression of procoagulant activity from APL blasts and may partially explain the amelioration of symptoms related to the coagulopathy. In addition, ATRA acts through the synthesis of u-PA inhibitors by APL blasts, thus downregulating cellular plasminogen activator activity. Also, it protects the endothelium from the prothrombolytic stimulus exerted by the inflammatory cytokines (TNF-␣, IL-1␤) produced by APL blasts. ATRA also interacts with the hemostatic system by increasing expression of TM (the surface high-affinity receptor for thrombin) on endothelial cells, resulting in stimulation of anticoagulant activity. Further, ATRA inhibits procoagulant activity of monocytes and regulates adhesion molecules expression on leukemic cells influencing their adhesion to the vascular endothelium. 63 In summary, ATRA is thought to exert an anticoagulant action that results from a combination of effects on leukemic, endothelial and monocytic cells.
At the clinical level, the impact of this agent in reducing early hemorrhagic deaths is still uncertain, as up to 10% of fatal hemorrhagic events were recorded in most recently reported trials. 72, 75, [100] [101] [102] [103] [104] [105] [106] [107] In particular, the results of two randomized studies comparing ATRA plus chemotherapy vs chemotherapy alone (European APL '91) 100 and ATRA vs chemotherapy (US Intergroup) 106 showed a tendency to a reduction of hemorrhagic deaths in patients given ATRA that did not reach statistical significance.
Front-line therapy
The results of recently conducted large clinical trials in newly diagnosed APL were presented by R Warrell (MSKCC, New York, USA), P Fenaux (for the European APL Group), G Avvisati (for the GIMEMA Group, Italy), M Tallman (for the US Intergroup), R Ohno (for the JALSG, Japan), A Burnett (for the MRC, UK) and MA Sanz (for the PETHEMA Group, Spain). The design of each study and the results obtained are summarized in Table 3 . Data from another recently published experience (MD Anderson Group), which were not reported in the 111 the advantage of using this agent in the front-line therapy was clearly established in early 1993 by the APL European Group who reported the results of a randomised study (APL-91) 100 comparing ATRA followed by chemotherapy (ATRA→CHT) with chemotherapy alone (CHT). In light of the significantly better relapse-free survival in the former group, the CHT arm was terminated early. 100 The results of successive studies, which in most cases aimed at determining the optimal ATRA plus CHT combination (sequential or ATRA→CHT, simultaneous or ATRA+CHT), clearly indicate better results in patients who are given ATRA+CHT. Patients included in these trials (Table 3) had CR rates of 72-95% and 3-4 years DFS rates of 62-75% with better figures obtained in those receiving the simultaneous combination (Refs 72,101,104-108 and Sanz MA, personal communication). Noteworthy, resistant leukemia was minimal or absent in studies where all patients had diagnosis confirmed at the genetic level (by karyotype and/or RT-PCR). Three trials 76, 104, 108 in which idarubicin was used as a single CHT agent together with ATRA provided further support to the notion that Ara-C may be omitted from induction therapy in this disease. [112] [113] [114] [115] Additional advantages of the ATRA+CHT combination include a better control of both ATRA syndrome and coagulopathy, the two most severe complications previously observed at high frequency using ATRA and CHT as separate agents. [1] [2] [3] [4] [5] In addition, prompt administration of steroids at the earliest symptoms of the syndrome, as recommended by the New York MSKCC Group, 101, 116 proved highly effective to prevent the development of an 'overt' syndrome. No more than 1-3% of deaths attributable to ATRA syndrome were recorded in these trials.
72,76,101,104-108
Consolidation
At least two cycles of intensive post-remission therapy were employed in all studies and currently represent the recommended approach for consolidation. These courses should mandatorily include anthracyclines, whereas the benefit of Ara-C is still unclear. Preliminary data from the MD Anderson 104 and PETHEMA 76 groups suggest that Ara-C may be omitted not only from induction but also from consolidation, though long-term results of these trials are required to clarify this issue. No studies have as yet attempted to compare different consolidation options in phase III trials and the role of Ara-C certainly represents one of the most important points to be addressed in the future. The vast majority of patients (up to 95%) are reported to achieve molecular remission -ie convert to PCR-negative for the PML/RAR␣ fusion gene -at the end of consolidation in the Italian, 108 
Maintenance
It has been proposed that APL, unlike other AML, may benefit from some type of maintenance therapy. In particular, two studies conducted prior to the ATRA era suggested the advantage of employing methotrexate (MTX) and 6-mercaptopurine (6-MP) as continuous or intermittent therapy after consolidation. 113, 118 In light of these data, and taking into account a potential role of ATRA in prolonging the DFS, the European APL '93 and the Italian GIMEMA trials randomized patients into four maintenance arms after the end of consolidation, ie MTX and 6-MP, ATRA alone (given intermittently, for 15 days every 3 months), ATRA + CHT, or observation. 107, 108 Preliminary results of both trials indicate an advantage of employing some type of maintenance. A better outcome in terms of DFS for patients receiving maintenance ATRA was also reported by the US Intergroup, although the continuous administration of retinoid therapy in this study was associated with significantly greater toxicity. 
Prognostic factors
Despite the significant improvement in survival achieved with the advent of ATRA + CHT combinations, a sizable proportion of APL patients still die of their illness. [1] [2] [3] [4] [5] 56, 57 Efforts aimed at ameliorating disease outcome include three main investigational areas, ie (1) improved control of the hemorrhagic syndrome; (2) identification of adverse prognostic features at presentation in order to better adapt the intensity of post-remission therapy in distinct risk-groups; and (3) early identification and rescue of recurrent disease (discussed below).
The impact of several clinical and biological parameters on CR rate and survival was analyzed in most of the clinical studies presented at the symposium. All investigators agreed that younger age and lower WBC at presentation were prognostic factors for longer EFS. As regards cut-off values, most studies considered 30 years for age and 10 × 10 9 /l for WBC. The UK MRC group showed there to be little difference between using 5 or 10 × 10 9 /l as the appropriate cut-off for WBC. 72 In the JALSG trial, absence of purpura at diagnosis, together with younger age and lower WBC was an additional favorable factor for CR achievement. 105 By contrast, several other biological features such as the type of PML/RAR␣ isoform, additional karyotypic abnormalities, and expression of the reciprocal RAR␣/PML transcript had no influence on either CR rate or overall survival. 72 ,75,101,104-107 A less favorable outcome for patients with the short PML/RAR␣ isoform, already described in a study of the MSKCC group, 119 was observed in the GIMEMA trial, but the difference with patients with the long transcript form was not statistically significant (unpublished observations). Similarly, a recent study of the US Intergroup reported the absence of prognostic significance of the two major PML/RAR␣ fusion types. 120 In a previous report, however, the same group observed a decreased response to ATRA in vitro in patients showing the rarest bcr2 (also referred to as 'variable') PML breakpoint type. 121 Importantly, the UK MRC study 72 demonstrated that a slower kinetics of PML/RAR␣ negativization was, together with presenting WBC greater than 10 × 10 9 /l, an independent predictor of adverse prognosis. In fact, detection of residual disease by RT-PCR immediately following the third consolidation course predicted an increased relapse risk associated with poorer overall survival (AK Burnett and D Grimwade, UK). 72 The prognostic impact of biological and clinical factors in APL patients receiving ATRA and CHT is summarized in Table 4 . 
Specific subsets: APL in children and in the elderly
APL has been variably reported as being more or less frequent in children than in adults, mainly depending on different geographic areas. For instance, the frequency of the disease seems much higher in children living in Italy than in those living in the USA. 122, 123 In addition, a higher prevalence of the microgranular type have been described in the pediatric population. 80, 122 Indeed, epidemiological studies that take into account potential bias due to misdiagnosis (eg lack of genetic validation, which is crucial in the M3v subtype) are needed to confirm these observations. Phenotypic and molecular features of APL in adult vs pediatric patients have been compared in a recent study presented in the symposium. 94 This analysis was conducted by multiparameter diagnostic characterization in a series of 196 cases with a molecularly confirmed PML/RAR␣-positive APL, including 133 adults and 63 children aged Ͻ15 years. In children, the disease was characterized by statistically significant more frequent incidence of the M3v subtype and of short PML/RAR␣ isoform or bcr3, and by higher WBC. CD2 was directly correlated with the M3v form in children and with bcr3 in adults. 94 A further difference observed in children is related to ATRA toxicity. Due to reported side-effects in the CNS, and particularly the occurrence of pseudotumor cerebri at higher frequency in children, 124 lower ATRA doses (ie 25 mg/m 2 ) have been given to patients aged Ͻ20 years in the ongoing Italian GIMEMA trial. 75 According to a preliminary study conducted in France, 125 such lower doses are equally effective, although it is not yet clear whether they are associated with less ATRArelated toxicity.
Besides adjusting ATRA dosage, the therapeutic approach for pediatric APL patients should be the same as that employed for adult cases. Retrospective studies 122, 123 analyzed by G Rivera (Memphis, USA) and data on children extrapolated from the US Intergroup 106 and the Italian GIMEMA 108 studies indicate that pediatric patients have similar response to treatment and overall outcome with respect to non-elderly adults when treated with CHT or modern ATRAcontaining regimens.
Prior to the advent of ATRA, elderly patients with APL had a dismal prognosis, much like the one of age-matched patients with other AML subtypes. 56 In addition to poorer tolerance to intensive therapy, these patients may show more frequent adverse biological features such as hyperleukocytosis and multidrug resistance P-170 protein and/or CD34 expression. However, no studies have as yet analyzed in detail the characteristics of genetically proven APL in the elderly, nor have these features been compared to those of younger patients.
The introduction of ATRA in the front-line therapy and its combination with CHT has considerably improved the prognosis of elderly patients with APL. Only one study has been reported to date which specifically analyzes clinical outcome in patients aged more than 60. 126 Together with data on the elderly population pooled from most recent trials, 72, 75, 101, [104] [105] [106] [107] [108] this study clearly shows a dramatic improvement in terms of either early mortality and relapsefree survival rates in patients receiving variable combinations of ATRA and CHT. Therapeutic results on 60 patients aged Ͼ60 enrolled in the Italian trial 'AIDA' were presented by MC Petti (Rome, Italy), who underlined the important progress achieved with this protocol. The results (85% CR and 57% 3-year EFS rates) compared favorably with respect to the pre-ATRA era. As expected, preliminary analysis of clinical out-come in this age subset also showed a reduced tolerance to consolidation therapy.
Therapy of relapse, new drugs and role of hemopoietic stem cell transplantation
The synthetic retinoic Am80 has been investigated by the Japanese group who showed a 58% CR rate in patients relapsed after ATRA. 127 In light of the long first CR duration in this cohort (median time: 22 months), it might be argued that ATRA would have been effective as well in these patients. However, this compound deserves further investigation and molecular and clinical data on a longer follow-up are currently awaited. Another retinoic derivative, 9-cis RA, has been employed at the MSKCC in New York for relapsed APL. 128 Unlike ATRA, 9-cis RA is able to activate both the RARs and RXRs pathways. 9, 10 However, preliminary data showed that, despite showing a more favorable pharmacokinetic profile, 9-cis RA was unable to overcome resistance in cases previously treated with ATRA. 128 It remains to be established whether there is any advantage in combining 9-cis RA, instead of ATRA, to anthracycline-containing CHT.
A number of pre-clinical studies have shown that certain arsenic (As) derivatives are effective against APL blasts in vitro. 50, [52] [53] [54] [55] At the clinical level, one study has been reported which suggests that As0 3 is a highly promising therapeutic strategy for APL in light of its specificity and limited toxicity. 51 Here again, no data are as yet available concerning response at the molecular level and remission duration in these patients. The putative mechanisms of action of As0 3 , which mainly acts as an apoptotic inducer, [50] [51] [52] [53] [54] [55] suggest a potential important role of this agent given as consolidation after cytotoxic drugs and/or differentiating agents, as discussed in the symposium by Z Chen (Shanghai, China). Preliminary data on refractory APL treated with As0 3 should be made available soon by the Shanghai and New York groups.
Given the outlook of newly diagnosed patients treated with combined ATRA+CHT, there is currently no indication for either allogeneic or autologous bone marrow transplantation (BMT) in first CR. Data from the EBMT registry, reviewed in the symposium by A Bacigalupo (Genova, Italy), currently provide only scarce information on recently treated patients and are mainly related to the pre-ATRA era. 129 For patients receiving autologous BMT in second remission, a leukemiafree survival of 31% has been reported in the last published analysis, but this report did not take into account the PCR status of grafted marrow. 129 Approximately 20 to 30% of patients treated with up-front state of art approaches have been reported to relapse. [1] [2] [3] [4] [5] 56, 57, 72, 75, [101] [102] [103] [104] [105] [106] [107] Although their outlook is reasonably optimistic, relapsed APL patients are at higher risk of early death and more frequently show refractory disease or a shortlived second remission. [1] [2] [3] [4] [5] 56, 57 First CR duration and, particularly, ability to undergo a second PCR-negative remission after reinduction are crucial determinants for successful outcome. As a general rule, these patients were considered candidates for aggressive therapy followed, when applicable, by autologous or allogeneic bone marrow transplantation. Second CR may be achieved with ATRA ± CHT in most cases, provided that first CR duration is у8 months. 5, 56, 57 Presence of detectable leukemia by RT-PCR after reinduction and consolidation should foster the choice of most aggressive approaches such as allogeneic BMT or experimental therapies using newly developed and potentially non-cross-resistant agents. For patients who achieve second molecular remission, autologous BMT (or peripheral blood stem cell infusion) is an effective and widely applicable approach. 130 Because of the promising, but yet scarce information presently available on the newly developed approaches (AM80, 9-cis RA, As0 3 , etc), treatment guidelines for relapsed patients are difficult to establish. Conventional therapies with ATRA and CHT ± BMT remain the most sound treatments although even in this context data are restricted to small series treated heterogeneously. [1] [2] [3] [4] [5] 56, 57, 129 In most institutions, aggressive consolidation followed by BMT would still be used, after ATRA-induced second CR, as a first option for relapsed APL. It is conceivable that rapid generation of data on the use of the above-mentioned novel compounds will change our routine approach to relapsed APL in the near future. Regardless of the therapeutic choice, the achievement of a stable second molecular CR should remain our therapeutic goal.
Minimal residual disease (MRD) and molecular relapse
Amongst all acute leukemias, APL is the only form in which a specific disease marker, ie the PCR amplifiable PML/RAR␣ fusion gene, allows molecular assessment of response to treatment and MRD evaluation in 100% of patients. The prognostic value of detecting MRD during clinical remission was initially suggested in Italy in 1992 131 and successively confirmed in numerous studies conducted in China, USA, Japan and several European countries. [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] Studies performed by using PCR assays capable of detecting one leukemic cell in a background of 10 3 -10 4 normal cells, agreed that a positive PCR test at completion of consolidation is strongly associated with impending clinical relapse. On the contrary, negative tests are not always associated with prolonged DFS and cure. In fact, a sizable proportion of patients who had tested negative post-consolidation were reported in the same studies to have relapsed thereafter. [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] Notwithstanding, it is worth noting that no patients in long-term survival are found PCRpositive using this sensitivity threshold. [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] This clearly indicates that a status of PML/RAR␣ PCR negativity is our best presently available therapeutic goal.
A number of complex technical issues were extensively debated which may account for difficulties in performing the PML/RAR␣ RT-PCR test, and which contribute to explain its relatively poor sensitivity. 5, 65, 144 Usually, RNA yield is poorer in APL as compared to other leukemias. In addition, low efficiency of the reverse transcription step, coupled to instability of the fusion gene are further factors related to frequently reported false negative results. 5, 65, 144 Some recent studies have outlined the possibility of improving the reaction sensitivity and specificity. For example, RNA denaturation before the reverse transcription step and/or use of the 'hot start' PCR technique have been reported as useful means to decrease the amplification of non-specific products and to allow more specific primer annealing, thereby resulting in increased sensitivity. 144, 145 Furthermore, employment of the more sensitive RAR␣/PML assay in conjunction with the conventional PML/RAR␣ reciprocal assay may lead to the detection of MRD in a greater number of patients, as discussed by D Grimwade (London, UK). 72, 141 The major drawbacks related to the clinical use of this reciprocal assay are related to its lack of expression at diagnosis in 20 to 30% of patients, 146 and to the occasional presence of residual transcripts in long-term survivors. 147 In the near future, a greater degree of inter-laboratory standardization should be made available through the input of automated, so-called 'real-time', quantitation of the fusion transcript.
Recently, a large prospective study of the Italian GIMEMA group confirmed the value of PCR positivity during remission as a predictor of clinical relapse. 148 In fact, of 21 patients who converted to PCR-positive at any time during follow-up, 20 underwent hematologic relapse within a median time of 3 months, whereas only eight of 142 patients who were repeatedly PCR-negative post-consolidation relapsed during followup. These data were obtained on a longitudinal prospective evaluation designed in 1993 in the context of the clinical GIMEMA multicenter trial, with pre-established time intervals for BM sampling, and centralized molecular biology evaluation using a PCR method allowing a sensitivity of 10 −4 . The results provide compelling evidence that MRD detection, at this sensitivity level is prognostically relevant in APL. 148 For these reasons, the GIMEMA group recently amended the ongoing trial by anticipating treatment of relapse at the time of minimal disease recurrence. In this respect, a status of molecular relapse was defined as the conversion from PCR-negative to PCR-positive after consolidation, confirmed in two successive bone marrow samples taken 2-4 weeks apart, and in the absence of morphologically detectable leukemic blasts in the bone marrow or peripheral blood. 148 F Lo Coco (Rome, Italy) presented preliminary data on treatment of molecular relapse. Reinduction therapy for these patients included standard doses of oral ATRA for 30 days followed by MTZ and Ara-C as consolidation and autologous BMT. Despite being too early for any conclusive statement, the study suggests some advantages in anticipating treatment of relapse at the time of minimal disease recurrence. 149 In fact, reinduction was associated with virtually no toxicity and could be administered on an outpatient basis. Moreover, in the majority of cases a second molecular remission was achieved with ATRA alone prior to chemotherapy consolidation, a result that is only sporadically obtained when ATRA is administered for overt relapse. 62, 149 Whether early therapeutic intervention on MRD will improve the overall survival of APL patients remains to be established on a longer follow-up.
Conclusions and future perspectives
A rather unusual simultaneity of important discoveries have paved the way, in the early 1990s, to the impressive improvement in prognostic outcome of APL patients obtained in recent years. Initial observations on the striking effect of differentiation therapy in this leukemia subset were immediately followed by identification of a disease-specific and pathogenically relevant gene abnormality. This concomitance, which soon translated into important insights in APL development and allowed the design of more rationale and diseasetargeted therapy, turned out to be essential for converting this once rapidly fatal malignancy into one of the most curable human leukemias. Indeed, survival curves of APL patients presented in this symposium are almost superimposable to those seen in childhood ALL.
For a number of reasons, APL represents a paradigm for the understanding of human leukemogenesis and for potential development of innovative therapeutic strategies. As discussed by TA Lister (London, UK) in his concluding remarks, areas of special interest include: (1) the complex mechanisms involved in leukemia-associated differentiation block and means to release the latter; (2) the existence of discrete genetico-clinical entities which are precisely defined at the molecular level and require targeted treatment; and finally (3) the possibility of improving survival by anticipating therapy of relapse in patients showing disease recurrence at the molecular level.
In spite of recent progress, APL remains nowadays a curable, yet not cured disease. Several major clinical problems still account for treatment failure, including early death and disease relapse. In addition, patient subsets that may benefit from more intensive therapy after remission induction have not yet been identified. The promising therapeutic potential of As0 3 and of other newly described agents still has to be validated by testing their efficacy at various time-points and in distinct combinations, including or not more conventional agents known to be active in the disease, such as retinoids and anthracyclines. Amongst other advances, early recognition and treatment of APL recurrence might represent a further step towards the final cure of all patients affected by this disease. As to this latter objective, we wish we could all have the chance of celebrating its achievement in the near future, hopefully during one of the forthcoming international meetings on APL. No matter where this announcement will be officially made, although no sites would appear to us more appropriate than the Eternal City.
